At the time of writing, Madrigal Pharmaceuticals Inc [MDGL] stock is trading at $444.64, up 7.83%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MDGL shares have gain 3.60% over the last week, with a monthly amount glided 0.53%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] stock has seen the most recent analyst activity on November 03, 2025, when BofA Securities upgraded its rating to a Neutral but kept the price target unchanged to $445 for it. Previously, Truist started tracking the stock with Buy rating on October 15, 2025, and set its price target to $580. B. Riley Securities upgraded its rating to a Buy and increased its price target to $422 on February 28, 2025. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $405 on February 27, 2025. In a note dated June 11, 2024, Wolfe Research initiated an Outperform rating and provided a target price of $382 on this stock.
For the past year, the stock price of Madrigal Pharmaceuticals Inc fluctuated between $265.00 and $463.62. Currently, Wall Street analysts expect the stock to reach $570 within the next 12 months. Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] shares were valued at $444.64 at the most recent close of the market. An investor can expect a potential return of 28.19% based on the average MDGL price forecast.
Analyzing the MDGL fundamentals
According to Madrigal Pharmaceuticals Inc [NASDAQ:MDGL], the company’s sales were 515.55M for trailing twelve months, which represents an 362.03% jump. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -0.6%, Pretax Profit Margin comes in at -0.55%, and Net Profit Margin reading is -0.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.38 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 409.78 points at the first support level, and at 374.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 474.73, and for the 2nd resistance point, it is at 504.81.
Ratios To Look Out For
It is important to note that Madrigal Pharmaceuticals Inc [NASDAQ:MDGL] has a current ratio of 3.44. As well, the Quick Ratio is 4.78, while the Cash Ratio is 0.97. Considering the valuation of this stock, the price to sales ratio is 19.22, the price to book ratio is 14.20.
Transactions by insiders
Recent insider trading involved William John Sibold, Officer and Director, that happened on Sep 09 ’25 when 7279.0 shares were purchased. President and CEO, Sibold William John completed a deal on Sep 09 ’25 to sell 7279.0 shares. Meanwhile, Former Director FRED CRAVES bought 2900.0 shares on Aug 29 ’25.
